✕
Gain Access to exclusive preclinical content.
Complete the form below to gain access to mattis aliquet nunc aliquam tempor. We’ll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
 简体中文 (Simplified Chinese) | 繁體中文 (Traditional Chinese)
HOW IT WORKS
Advancing fluorescent tracer agents and their transdermal detection.

The goal of MediBeacon’s fluorescent tracer agent-based systems is to provide clinically relevant information that can cost effectively and positively impact patient care.

Accurate physiological measurements made at the point of care, are vital in the critical care setting as well as in the management of chronic diseases. Fluorescent tracer agent-based monitoring systems are well positioned to provide measured GFR, GI permeability quantification, enhanced visualization of the vasculature during ocular angiography, and identification of the ureters during abdominal surgeries.*
NOVEL FLUORESCENT TRACER AGENTS
The goals in the development of fluorescent tracer agents for physiological monitoring are to:
  • Engineer molecules that do not interact with the body.
  • Optimize molecules so they may be optimally detected by transdermal sensors.

USE IN NEPHROLOGY*

The MediBeacon Transdermal GFR Measurement System (TGFR) is comprised of three distinct parts.

Lumitrace™ (relmapirazin) a novel and proprietary fluorescent tracer agent is intravenously administered to a patient and then subsequently excreted from the body by the kidneys.

A small transdermal sensor containing the light source and photo detector for the noninvasive detection of the transdermal fluorescence from Lumitrace™ is attached to one of several positions on the body using a biocompatible adhesive. This transdermal sensor has a built-in cable that connects to the monitor.

The display monitor provides power to the transdermal sensor, digitizes the data acquired from the sensor, contains the algorithms to run the sensor and convert the output to GFR, and displays the GFR to the clinician and/or caregiver.

Together, the components described above are designed to allow the determination of measured GFR. The goal of the TGFR is to provide a minimally invasive measure of the change in patient levels of tracer agent over time via the transdermal sensor placed on the patient’s skin. The rate of decrease in the emitted fluorescence from Lumitrace™ (relmapirazin) is automatically calculated and displayed on the monitor thus yielding a continuous measured Glomerular Filtration Rate (mGFR) or kidney function. Watch the animation.

✕

MB-102 brand name is Lumitrace™

USE IN GASTROENTEROLOGY*

Orally administered fluorescent tracer agents
The oral administration of fluorescent tracer agents coupled with transdermal detection technology is being adapted to provide clinically practical measurement of gut permeability.
LIMITLESS POSSIBILITIES

Patient administered fluorescent tracer agent-based systems focus on the adaptation of fluorescent tracer agent-based systems for use in the outpatient and eventually, in-home setting are important initiatives.

United States
425 N. New Ballas Road
Suite 100
St. Louis, MO 63141
P: (314) 735-0968

Germany
Cubex41
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
P: +49 (0)621-150283-15

Greater China
Huadong Medicine Co., Ltd
Telephone: 4008-269-985
+86-(0)571-89908581
Zip: 310011
Address: No.866. Moganshan Road, Hangzhou, Zhejiang Province, China
Email: info@eastchinapharm.com

Science How it Works R&D Platform Product Pipeline Patent Estate Preclinical Clinical Focus Areas Nephrology Gastroenterology Ophthalmology Surgery In Discovery Investors Why It's Important Company Overview By the Numbers
Publications MediBeacon Publications Preclinical Publications Industry Literature Company History People Quality Commitment News/Media Contact Get Updates Investors General Questions

*MediBeacon products are in various stages of clinical development and are not yet approved for human use.

**The Transdermal GFR Measurement System (TGFR) is intended to measure Glomerular Filtration Rate (GFR) in patients with impaired or normal renal function. References on this website to measured kidney function and measured renal function refer to the measured GFR.

Terms and Conditions | Privacy Policy | © 2021 MediBeacon All Rights Reserved.

COOKIE CONSENT: We use cookies and similar technologies to recognize your repeat visits and preferences, as well as to analyze traffic, among other things. To learn more about cookies, view our Privacy Policy. By clicking “I Accept” on this banner, or using our site, you consent to the use of cookies unless you have disabled them.